Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling

Blood (2012) 119 (16): 3757–3766.

https://doi.org/10.1182/blood-2011-05-349662

Published: 2012

Includes: Supplemental data

Journal Articles

Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report.

Stanton Goldman, MD, James Lynch, PhD, Lauren Harrison, RN, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 104.

https://doi.org/10.1182/blood.V114.22.104.104

Published: 2009

Journal Articles

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Nancy Day, Ph.D., Janet Ayello, MS, MT, Carmella van de Ven, MA, Megan S Lim, MD, PhD, Sherrie L. Perkins, MD, PhD, Warren Sanger, PhD, Lauren Harrison, RN, Stanton Goldman, MD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 1928.

https://doi.org/10.1182/blood.V114.22.1928.1928

Published: 2009

Journal Articles

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Mitchell S. Cairo, MD, James Lynch, PhD, Lauren Harrison, RN, Carmella van de Ven, MS, Thomas Gross, MD, PhD, Bruce Shiramizu, MD, Warren Sanger, PhD, Sherrie L. Perkins, MD, PhD, Stanton Goldman, MD

Blood (2008) 112 (11): 838.

https://doi.org/10.1182/blood.V112.11.838.838

Published: 2008

Journal Articles

Mutations in the DNA-binding codons of TP53 , which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma

Ken H. Young, Dennis D. Weisenburger, Bhavana J. Dave, Lynette Smith, Warren Sanger, Javeed Iqbal, Elias Campo, Jan Delabie, Randy D. Gascoyne, German Ott, Lisa Rimsza, H. Konrad Müller-Hermelink, Elaine S. Jaffe, Andreas Rosenwald, Louis M. Staudt, Wing C. Chan, Timothy C. Greiner

Blood (2007) 110 (13): 4396–4405.

https://doi.org/10.1182/blood-2007-02-072082

Published: 2007

Includes: Supplemental data

Journal Articles

Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.

Georg Lenz, MD, Inga Nagel, PhD, Reiner Siebert, MD, Warren Sanger, MD, George W. Wright, PhD, Hong Zhao, Andreas Rosenwald, MD, Hans-Konrad Muller-Hermelink, MD, Randy D. Gascoyne, MD, Elias Campo, MD, Elaine S. Jaffe, MD, Erlend B. Smeland, MD, Richard I. Fisher, MD, W. Michael Kuehl, MD, Wing C. Chan, MD, Louis M. Staudt, MD, PhD

Blood (2006) 108 (11): 356.

https://doi.org/10.1182/blood.V108.11.356.356

Published: 2006

Journal Articles

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Philip Bierman, MD, Fausto Loberiza, MD, Bhavana Dave, PhD, Warren Sanger, PhD, R. Gregory Bociek, MD, Martin Bast, BS, Julie M. Vose, MD, James Olen Armitage, MD, Dennis Weisenburger, MD

Blood (2006) 108 (11): 2030.

https://doi.org/10.1182/blood.V108.11.2030.2030

Published: 2006

NARROW

Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Mutations in the DNA-binding codons of TP53 , which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma

Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report

Mutations in the DNA-binding codons of TP53 , which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma

Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only